Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology is Scopus-indexed (Q1, CiteScore 19.8), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley & Sons Inc..
Checked against the index lists dated .
ISSN 1939-0041Verify ISSN ↗1939-5116Verify ISSN ↗
Publisher: John Wiley & Sons Inc.
Cost to publish: About US$4,730 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 7 / 466 | 98th | Q1 |
| Biomedical Engineering | 13 / 342 | 96th | Q1 |
| Bioengineering | 12 / 168 | 93rd | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q1, CiteScore 19.8.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology is Q1 in Medicine (miscellaneous) (rank 7 of 466), Q1 in Biomedical Engineering (rank 13 of 342) and Q1 in Bioengineering (rank 12 of 168), by CiteScore 2025.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 19.8, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.565, quartile Q1, with an H-index of 114.
The publisher lists an article processing charge of about US$4,730 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology is published by John Wiley & Sons Inc. Its print ISSN is 1939-0041 and its online ISSN is 1939-5116.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology has an h-index of 123 and a 2-year mean of 9.87 citations per paper (OpenAlex). Its Scopus CiteScore is 19.8, quartile Q1. On 2-year citations it ranks #11 of 451 Scopus journals in Medicine (miscellaneous).
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology published 59 papers in 2025; its busiest recent year was 2022 with 110. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from China (30.7%), United States (25.8%) and India (5.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.